Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | belantamab mafodotin-blmf |
Trade Name | Blenrep |
Synonyms | anti-BCMA ADC GSK2857916|J6M0-mcMMAF|GSK2857916 |
Drug Descriptions |
Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262). Blenrep (belantamab mafodotin-blmf) is FDA approved for use in patients with relapse or refractory multiple myeloma who have received 4 or more prior therapies (FDA.gov). |
DrugClasses | TNFRSF17 Antibody 20 |
CAS Registry Number | 2050232-20-5 |
NCIT ID | C114299 |